Ginascol John F 4
4 · ABBOTT LABORATORIES · Filed Sep 3, 2020
Insider Transaction Report
Form 4
Ginascol John F
Executive Vice President
Transactions
- Exercise/Conversion
Common shares without par value
2020-09-01$47.00/sh+12,012$564,564→ 76,689 total - Exercise/Conversion
Common shares without par value
2020-09-01$44.40/sh+39,953$1,773,913→ 136,775 total - Exercise/Conversion
Option (right to buy)
2020-09-01−12,012→ 45,709 totalExercise: $47.00From: 2018-02-20Exp: 2025-02-19→ Common shares (12,012 underlying) - Exercise/Conversion
Common shares without par value
2020-09-01$38.40/sh+20,133$773,107→ 96,822 total - Exercise/Conversion
Option (right to buy)
2020-09-01−20,133→ 0 totalExercise: $38.40From: 2019-02-19Exp: 2026-02-18→ Common shares (20,133 underlying) - Exercise/Conversion
Option (right to buy)
2020-09-01−39,953→ 0 totalExercise: $44.40From: 2020-02-17Exp: 2027-02-16→ Common shares (39,953 underlying) - Tax Payment
Common shares without par value
2020-09-01$109.47/sh−47,772$5,229,601→ 89,003 total
Footnotes (1)
- [F1]Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.